Haematopoietic stem cell number is not solely defined by niche availability.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Advances in natural killer cell immunotherapy for hematologic malignancies.Cancer biology & therapy · 2026
   Review
2. The Evolution of Polyclonal Competition in Aging Hematopoiesis.Cancer discovery · 2026
   Article
3. From complexity to clarity: aging bone marrow niche in bone and blood regeneration and malignancy.Bone research · 2026
   Review
4. The bone marrow microenvironment during homeostasis and after myeloablation.Journal of bone and mineral metabolism · 2026
   Review
5. Microneedle-Assisted Cell Delivery and Therapy.Research (Washington, D.C.) · 2026
   Review

Corrections and comments

• Update of
  Haematopoietic stem cell numbers are not solely determined by niche availability.2023

Authors and funding

10 authors.

Funding

Abstract

Indexed as